

**April 30, 2026**

To,  
The Listing Department,  
**BSE LIMITED,**  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort  
Mumbai- 400 001

To,  
The Listing Department  
**National Stock Exchange of India Limited,**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C-1,  
G-Block, Bandra Kurla Complex,  
Mumbai -400051

**Scrip Code: 543349**

**NSE Symbol: ACUTAAS**

**Subject: Press Release pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam,

In accordance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Press Release discussing the fourth quarter & year ended financial results as on March 31, 2026.

This Press Release will be available on the website of the Company [www.acutaas.com](http://www.acutaas.com).

Kindly take the same on record.

Yours faithfully,  
For, **ACUTAAS CHEMICALS LIMITED**



**Ekta Kumari Srivastava**  
**Company Secretary & Compliance Officer**

Encl: Press Release

## Acutaas Chemicals Limited reports Q4 & FY26 Results

**Q4 FY26 Revenue from Operation at ₹4,328mn, up 40.3% YoY**

**Q4 FY26 PAT at ₹1,343mn, up 114.1% YoY; PAT Margins at 31.0%**

**Surat, April 30, 2026:** Acutaas Chemicals Limited (BSE: 543349, NSE: ACUTAAS), a leading global manufacturer of advance pharmaceutical intermediates and speciality chemicals, today announced financial results for the quarter and year ended March 31, 2026.

### Consolidated Financial Results – Q4 & FY26:

Particulars (Rs. Mn)	Q4FY26	Q4FY25	YoY	Q3FY26	QoQ	FY26	FY25	YoY
Revenue from Operations	4,328	3,085	40.3%	3,932	10.1%	13,394	10,069	33.0%
Gross Profit	2,683	1,460	83.8%	2,240	19.8%	7,734	4,547	70.1%
Gross Margin	62.0%	47.3%		57.0%		57.7%	45.2%	
EBITDA	1,835	850	116.0%	1,507	21.8%	4,804	2,321	107.0%
EBITDA Margin	42.4%	27.5%		38.3%		35.9%	23.0%	
PAT	1,343	627	114.1%	1,062	26.4%	3,564	1,604	122.2%
PAT Margin	31.0%	20.3%		27.0%		26.6%	15.9%	

Commenting on results, Mr. Naresh Patel, Executive Chairman & Managing Director, Acutaas Chemicals Limited, said: “I am pleased to report a strong close to FY26, with Q4 revenue from operations reaching Rs. 4,328 million — up 40.3% year-on-year — and our highest ever PAT margin of 31.0%.

Our strategy is clear: build a diversified chemicals business across three high-growth verticals — Battery Chemicals, Semiconductors, and Pharmaceutical CDMO. By scaling these in parallel, we are de-risking our revenue base while creating multiple independent engines of compounding, long-term growth.

We enter FY27 from a position of strength. I am confident of delivering 25% revenue growth in FY27.”

### Key Results & Business Highlights (Q4FY26 Consolidated):

- ✓ Revenue from operations for Q4FY26 grew by **40.3% YoY to Rs. 4,328 mn**
- ✓ The **gross margin** for the quarter improved to **62.0%** up 1,470 bps YoY
- ✓ **EBITDA** for the quarter came at **Rs. 1,835 mn** up 116.0% YoY
- ✓ **EBITDA margin** for the quarter was at **42.4%** as compared to 27.5% in Q4FY25
- ✓ **PAT** for the quarter was **Rs. 1,343 mn** up 114.1% as compared to PAT of Rs. 627 mn in Q4FY25
- ✓ The **PAT margin** for the quarter was at **31.0%** up 1,070 bps YoY

**PRESS RELEASE**

For Immediate dissemination



**ABOUT ACUTAAS CHEMICALS LIMITED:**

Acutaas Chemicals Limited is a speciality chemicals manufacturer serving a wide range of industries, including pharmaceuticals, semiconductors, battery chemicals, personal care, agrochemicals, and fine chemicals. Our core strength lies in the research-driven development and manufacturing of advanced pharmaceutical intermediates used in both regulated and generic APIs, as well as intermediates for New Chemical Entities (NCEs).

We are also expanding our portfolio to include high-value speciality chemicals for emerging technologies such as battery materials, semiconductor, and next-generation electronic applications.

**CAUTIONARY STATEMENT:**

*This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Acutaas Chemicals Limited has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.*

**For details, please contact:**

<b>Investor Relations at Acutaas Chemicals Limited</b> <b>Senior Manager – Investor Relations</b> Mr. Rahul Thakur <a href="mailto:Rahul.thakur@acutaas.com">Rahul.thakur@acutaas.com</a>	<b>Registered Office</b> Plot no. 440/4, 5 & 6, Road No. 82/A, GIDC Sachin, Surat- 394230 CIN: L24100GJ2007PLC051093 ISIN: INE00FF01025 NSE Code: ACUTAAS BSE CODE: 543349 Website: <a href="http://www.acutaas.com">www.acutaas.com</a>
--	---